The good news keeps flowing at Isis (ISIS +0.2%) this week (see I, II) as the FDA grants...

The good news keeps flowing at Isis (ISIS +0.2%) this week (see I, II) as the FDA grants fast-track designation for the company's ISIS-TTR drug for treating familial amyloid polyneuropathy (FAP), a rare genetic disease that is a form of transthyretin amyloidosis and leads to the loss of nerve function and wasting. Isis is developing ISIS-TTR with GSK (GSK -0.4%) to treat transthyretin amyloidosis and the companies hope to start Phase 2/3 trials this month.

From other sites
Comments (4)
  • mc10010
    , contributor
    Comments (196) | Send Message
    Again, no confirmation from the market. This news for any other company would of moved the value needle up. Not the case with ISIS.Same story for the last 15 years. News but no value added to shareholders.


    The market has never confirmed this technology, though the announcements this week support it. Hopefully, before I die I will see my 15 year investment show a return.
    13 Dec 2012, 10:45 AM Reply Like
  • guyrhansen
    , contributor
    Comments (20) | Send Message
    Great opportunity to keep adding to your position.
    13 Dec 2012, 12:09 PM Reply Like
  • arthurs1
    , contributor
    Comments (394) | Send Message
    One day it will be Mount St Helen's.....and then again and again.
    13 Dec 2012, 01:35 PM Reply Like
  • ronatinsky7
    , contributor
    Comments (2) | Send Message
    your right..15 years and a yo yo but always going back down
    13 Dec 2012, 02:25 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs